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Abstract
Background: In case of cow’s milk allergy (CMA), pediatric guidelines recommend for children the use of
extensively hydrolyzed formulas (eHFs) as elimination diet. According to the American Academy of Pediatrics, the
hypoallergenicity of each specific eHF should be tested in subjects with CMA.
Methods: A prospective, multicenter trial was performed to assess the tolerance/hypoallergenicity of a thickened
casein-based eHF (eHCF, Allernova AR®, United Pharmaceuticals, France) in infants aged <12 months with CMA
proven by a double-blind placebo-controlled food challenge. Its efficacy, measured through allergy symptoms
monitoring and Cow’s Milk-related Symptom Score (CoMiSS) calculation, and safety were evaluated during a 4-
month feeding period. Growth z-scores were computed based on WHO anthropometric data.
Results: Thirty infants (mean age: 4.8 ± 3.0 months) with CMA proven by a DBPCFC tolerated the eHCF during the
4-month study. The CoMiSS, crying and regurgitation scores significantly decreased by 4.2 ± 4.0, 0.9 ±1.2 and 0.7 ± 1.
1 respectively, after 14 days of feeding (p < 0.001). The Scoring Atopic Dermatitis index, of 33.2 ± 14.8 at inclusion in
9 patients, significantly decreased by 15.5 ± 6.7 and 21.1 ± 11.2, after 14 and 45 days of feeding, respectively (p < 0.001).
The percentage of infants having normal stool consistency (soft or formed stools) significantly improved from 66.7 %
(20/30) at inclusion to 90.0 % (27/30) after 14 days of feeding (p = 0.020). The growth z-scores, negative at study
inclusion, significantly improved over the 4-month study. No adverse event was related to the eHCF.
Conclusion: The thickened eHCF was tolerated by more than 90 % of included allergic infants with 95 % confidence
interval and can therefore be considered as hypoallergenic in accordance with current guidelines. The improvement of
growth indices and absence of related adverse events confirmed its safety. Results of this trial back the use of the
tested thickened eHCF as an efficient and safe alternative in children with CMA.
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Background
Cow’s milk allergy (CMA) is an immune-mediated reac-
tion which can either be antibody-driven (IgE-mediated)
or cell-mediated (non-IgE-mediated) or mixed, and
elicits reactions which are reproducible upon re-
exposure to cow’s milk proteins (CMP) [1]. Estimates of
CMA prevalence depend on the diagnosis procedure
used; recently, a meta-analysis stated an overall pooled
estimate for 0–1 year old infants of point prevalence of
CMA reported by parents of 4.2 % (95 % confidence
interval (CI): 3.2–5.4), decreasing to 2.0 % (1.5–2.5)
when CMA was proven with a double-blind placebo-
controlled food challenge (DBPCFC) [2]. CMA manifests
through diverse and non-specific symptoms, rendering
the CMA diagnosis very difficult [3–5]. CMA symptoms
mainly concern the cutaneous area, the respiratory and
gastrointestinal tracts but can also be general [3–6]. The
DBPCFC is therefore considered as the gold standard
for CMA diagnosis [4, 6, 7]. CMA treatment consists in
the elimination of any source of non-hydrolyzed CMP
from the diet, which is mainly achieved in children by
using extensively hydrolyzed formulae (eHFs) based on
cow’s milk [4–6, 8]. As the molecular weight profile of a
given hydrolysate cannot predict potential reaction in a
given child [9], the American Academy of Pediatrics rec-
ommended that tolerance/hypoallergenicity of any for-
mula intended for allergic children should be clinically
tested in that specific population [10]. eHFs should also
be tested for their growth adequacy in allergic children
[6, 8, 11] as CMA may result in growth retardation [12].
Regurgitations, which are the most typical presentation
of infantile gastro-esophageal reflux, are common com-
plaints in infancy [13]. Although they may be a symptom
of CMA, they may also occur in allergic infants inde-
pendently of their allergic disease. To effectively manage
both conditions in infants, the new eHF based on casein
(eHCF) tested in this trial has been thickened. Therefore,
this trial was aimed at evaluating the tolerance/hypoal-
lergenicity of the thickened eHCF in infants with CMA
proven through DBPCFC, as well as its efficacy on
allergy symptoms and its impact on growth during a 4-
month feeding period.
Methods
Study population
Infants aged between 1 and 12 months with CMA, ei-
ther confirmed through a DBPCFC within 3 months
prior to inclusion, or highly suspected based on specific
suggestive symptoms, were included in this prospective,
multicenter study. The main exclusion criteria were: in-
fants mainly or exclusively breastfed with mother’s will-
ingness to continue breastfeeding, infants who would
need an amino acid-based formula (AAF) according to
pediatric recommendations [3, 4], infants fed an eHF
with no improvement of their allergy symptoms, infants
who refused to drink an eHF any time prior to inclusion
and infants fed the non-thickened version of the tested
formula. At study enrolment, if CMA was not already
diagnosed by a DBPCFC, such a challenge had to be per-
formed within the 3 months following inclusion. In case
of negative challenge, subject’s participation in the trial
ended and the patient was included in the Safety popula-
tion (defined in Study outcomes) only. The challenge was
performed according to guidelines [3]: in short, the child
was fed on two different days with volumes being in-
creased every 20 min under medical supervision of ei-
ther an AAF (Neocate®, Nutricia, Germany) as placebo
or a formula which blended two thirds of a standard
CMP-based infant formula with one third of Neocate® to
ensure double-blinding. The child was observed for 2
additional hours after the last dosage administration to
monitor immediate reactions. After completion of both
challenge days, in the absence of immediate reaction to
CMP, the child had to drink at least 250 ml per day of a
standard CMP-based formula for up to one week [3]. At
home, parents monitored the appearance of delayed al-
lergy reactions and reported them to the physician. In case
of delayed allergy reaction, the exclusive bottle-feeding of
the tested formula was immediately reinitiated. If no reac-
tion occurred either during both challenge test days or
during one-week feeding with the standard CMP-based
formula, cow’s milk challenge was considered negative
and CMA diagnosis was excluded.
Study formula feeding
Infants were exclusively bottle-fed the tested formula
(Allernova AR®, Novalac, United Pharmaceuticals,
France) for 4 months. The tested formula contains an
extensively casein-based hydrolysate as protein source
and is thickened with a patented complex containing fi-
bers (0.5 g/100 ml), mainly composed of pectin, to re-
duce regurgitation but also to help intestinal transit
regulation. Its nutritional composition complied with the
applicable European regulation, particularly regarding
the amino acid profile.
Study outcomes
The primary outcome was the tolerance/hypoallergeni-
city of the tested formula, defined as the absence, in in-
fants with a proven CMA, of any allergy symptoms that
led to study discontinuation during the first two weeks.
It was evaluated on patients in the Tolerance/Hypoaller-
genicity population, i.e. all patients fed the tested for-
mula at least once and for whom the CMA was proven.
Patients fed the tested formula at least once formed the
Safety population. The secondary outcomes were the ef-
ficacy of the studied formula on allergy symptoms
(mainly including the evolution of the Cow’s Milk-
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related Symptom Score [14] and the main CMA symp-
tom), its impact on growth parameters and on parents
and investigators satisfaction. These outcomes were
assessed on the Full Analysis Set (FAS) population com-
prising patients from the Safety population with evalu-
ation of the main efficacy criterion at baseline and at
2 weeks. Adverse events (AEs) were registered in pa-
tients in the Safety population.
Study interventions
Visits were planned 14, 45, 90 and 120 days after inclu-
sion. Other CMA diagnosis tests, dosage of serum IgE
specific to cow’s milk (sIgE), skin prick test (SPT) and
atopy patch test (APT), were performed if deemed ne-
cessary by the physician according to his usual practice;
when carried out before study inclusion, the results of
these tests were also collected. From serum, sIgE were
analyzed with enzymatic immunoassay (Phadia 100
ThermoFisher Scientific CAP system), the limit of detec-
tion being 0.1 kU/l. For SPT, commercial UHT milk,
and histamine dihydrochloride (10 mg/ml) and isotonic
saline solution (NaCl 0.9 %) as positive and negative
control, respectively, were applied to the patients’ volar
forearm. SPT were performed using a 1-mm single peak
lancet (ALK, Copenhagen, Denmark) in Italy and Staller-
point® (Stallergenes SA, France) in France and Belgium.
Reactions were recorded on the basis of the largest
diameter (in millimeters) of the wheal and flare at
15 min. The SPT result was considered “positive” if the
wheal diameter induced by cow’s milk minus that in-
duced by negative control was larger than 3 mm. For
APT, 1–2 drops of commercial UHT milk was placed on
filter paper and applied with adhesive tape to the un-
affected skin of the child’s back, using 12-mm aluminum
cups (Finn Chambers® on Scan pore). Isotonic saline so-
lution was the negative control. The occlusion time was
48 h and results were read 20 min and 24 h after
removal of the cups. The test result was considered posi-
tive if at least a significant erythema was present. IgE-
mediated was defined as having either positive sIgE or
positive SPT to cow’s milk.
Parents were instructed to eliminate any milk or dairy
products from the diet throughout the entire study and
to not introduce hen’s egg, soy protein, peanut or any
new food in their infant’s diet in the first two weeks of
the study. Patient selection was performed in hospital
outpatient clinics and private practices in France,
Belgium and Italy.
Study measurements
During 3 days before each visit, parents were asked to
record data on formula intake, number of regurgitations,
stool patterns and duration of crying. At inclusion and
each follow-up visit, the presence and severity of CMA
symptoms were registered by the same investigator,
based on clinical examination and parents report. CMA
symptoms were itemized for each concerned area: cuta-
neous (urticaria, angioedema and eczema, the severity of
the latter being assessed as mild, moderate or severe, on
head, neck and trunk and on arms, hands, legs and feet),
respiratory symptoms (such as wheezing, rhinitis, bron-
chitis, bronchospasm, their severity being assessed as
slight, mild or severe), digestive (regurgitations assessed
through the regurgitation scale defined by Vandenplas
et al. [15], vomiting, bloody stools, stool consistency
assessed through the Bristol stool scale [16]), and digest-
ive discomfort as general symptom (mild, moderate or
severe intensity and reflected by abdominal pain, gas,
bloating and irritability). Daily unexplained crying time
was registered through a scale with the following points:
less than one hour/day, 1–1.5 h/d, 1.5–2 h/d, 2–3 h/d,
3–4 h/d, 4–5 h/d and more than 5 h/d. During a work-
shop held in 2014, a Cow’s Milk-related Symptom Score
(CoMiSS) was defined [14]. It comprises five items
(crying, regurgitations, stool consistency, skin and re-
spiratory symptoms), which were all assessed during the
study, enabling the calculation of the CoMiSS for each
infant at each visit. Eczema severity was assessed using
the Scoring Atopic Dermatitis index (SCORAD) [17], as
this score is a valid tool, commonly and easily used by
hospital physicians. Because of the diversity of CMA
symptoms in general [3–5], the pediatrician had to de-
termine the main CMA symptom for each subject at
baseline, and assess its evolution at each follow-up visit.
At each visit, the pediatrician measured weight, length
and head circumference and registered stool frequency,
sleep quality (either agitated, i.e. excessive waking with
no clear cause, or quiet, i.e. absence of or few awaken-
ings) and adverse events (AEs).
Statistical analysis
In order to be considered hypoallergenic, a formula
must demonstrate that with 95 % CI, it does not provoke
allergic reactions in 90 % of subjects with confirmed
CMA [10]. In case of no reaction, a sample size of 29
participants is sufficient.
For quantitative parameters, intra-group changes were
analysed using the Student’s test or Wilcoxon’s test (non-
normal data). For qualitative parameters, changes from
baseline within treatment group were analysed by sym-
metry test, or by McNemar test for binary variables. Statis-
tical analyses were conducted using SAS version 9.2 (SAS
Institute Inc., United States). Significance was set at p <
0.05. Weight-for-age (WFA), length-for-age (LFA), weight-
for-length (WFL), body mass index (BMI)-for-age and head
circumference-for-age (HCA) z-scores were computed
based on WHO anthropometric data [18]. The CoMiSS
was calculated for each patient and at each visit [14].
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The study design was approved by independent ethic
committees: Ile-de-France III (Paris, France), Medical
Ethics Committee of the Regional Hospital of Namur
(Belgium) and Ethics Committee of the University of
Naples, Federico II. This study was conducted in accord-
ance with ethical standards laid down by the Declaration
of Helsinki. Parents, or others legally responsible for the
infants, provided written consent regarding their accept-
ance to participate and the study procedures.
Results
Thirty two infants were included in 3 centers from
November 2013 to July 2014. CMA was confirmed in 30
of them through a DBPCFC and therefore constituted
the hypoallergenicity population (Fig. 1). One infant tol-
erated a cow’s milk-based formula introduced by his par-
ents 5 days after study inclusion, excluding the CMA
diagnosis. Another infant dropped out of the study be-
fore CMA could be confirmed because of his parents’
wish to withdraw. According to the investigator, it was
not due to any medical reason, and the patient could
have continued to participate in the study. All those 30
infants completed the 4-month study.
Main baseline characteristics of included subjects are
described in Table 1 and Additional file 1 [19, 20].
70.0 % (21/30) of infants had IgE-mediated CMA. At
Fig. 1 Study flow chart. N: number of subjects
Table 1 Main demographic and clinical characteristics of FAS
population (N = 30) at inclusion
Characteristics
Boys, N (%) 18 (60.0)
Age, mean (± SD), months 4.8 (3.0)
Gestational age, mean (± SD), weeks 38.7 (1.0)
WFA z-score at birth, mean (± SD) −0.1 (1.1)
LFA z-score at birth, mean (± SD) 0.0 (1.3)
Feeding history
Ever breastfed, N (%) 25 (83.3)
Duration of exclusive breastfeeding, mean
(± SD), weeks
11.5 (7.7)
Duration of partial breastfeeding, mean (± SD),
weeks
8.5 (6.1)
Type of feeding at study entry, N (%)
Exclusively formula-fed 29 (96.7)
Partially breast-feda 1 (3.3)
Type of formula used before study inclusion, N
(duration of use, mean ± SD, weeks)
Non-hydrolyzed CMP-based formula 6 (8.5 ± 5.0)
Extensively hydrolyzed formula based on CMP 13 (6.2 ± 8.8)
Amino acid-based formula 6 (2.7 ± 1.1)
Vegetable-based formula 5 (2.6 ± 2.1)
Anthropometric data
WFA z-score, mean (± SD) −0.8 (0.8)
LFA z-score, mean (± SD) −0.7 (1.0)
WFL z-score, mean (± SD) −0.4 (1.1)
BMI-for-age z-score, mean (± SD) −0.6 (1.0)
HCA z-score, mean (± SD) −0.3 (1.2)
Allergy characteristics
Family history of allergy‡, N (%) 10 (33.3)
Age at onset of allergy symptoms, mean (± SD),
months
2.5 (2.3)
Time since the start of the exclusion diet, median
[min – max; IQR], weeks
2.7 [0.0–36.0; 1.1–6.3]
Delay between onset of allergy symptoms and start
of exclusion diet, median [min – max; IQR], weeks
1.3 [0.0–34.9; 0.6–4.1]
Types of first allergy symptoms, N (%)
Exclusively digestive 17 (56.7)
Exclusively cutaneous 10 (33.3)
At least two concerned areas 3 (10.0)
CMA diagnosis tests, number of subjects with
positive reactions/number of subjects with test
performed (%)
Atopy patch test to CMP 8/18 (44.4)
Skin prick test to CMP 20/30 (66.7)
Serum IgE specific to CMP 3/6 (50.0)
N number of subjects, min minimum, max maximum, IQR interquartile range
athe mother excluded CMP from her regimen; ‡at least one parent or sibling
with confirmed allergy
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inclusion, 80.0 % of infants (24/30) were on elimination
diet. DBPCFC was performed for 16.7 % of patients at a
median of 3.9 [range: 0.1-8.7] weeks before study inclu-
sion, and during study course for 83.3 % of infants, at a
median of 0.4 [0.1-11.3] weeks after study inclusion. 22
patients had immediate reactions to CMP during the
DBPCFC (Table 2).
No infant from the Tolerance/Hypoallergenicity popu-
lation dropped out of the study and all of them tolerated
the tested formula.
The main CMA symptom was digestive for 63.3 %
(19/30) of infants, cutaneous for 33.3 % (10/30) of in-
fants and general for one infant. It was resolved or im-
proved as of day 14 for 83.3 % of the patients (p < 0.001,
proportion test) and for 100 % of patients within 45 days.
The mean (± standard deviation (SD)) CoMiSS, regurgi-
tation and crying scores significantly decreased by 4.2
(±4.0), 0.7 (±1.1) and 0.9 (±1.2) respectively after 14 days
of feeding (Table 3). At inclusion, 90.0 % (27/30) of
infants cried ≥1.5 h per day, significantly decreasing
to 66.7 and 46.7 % after 14 and 45 days respectively
(p = 0.020; p < 0.001, McNemar test). At inclusion, 3
patients had angioedema, this symptom disappearing
after 14 days. 9 patients had eczema at inclusion with
a mean (±SD) SCORAD index of 33.2 (±14.8) which
significantly decreased by 15.5 (±6.7) and 21.1 (±11.2)
after 14 and 45 days, respectively (p < 0.001, Student’s
test). At inclusion, 22 infants experienced vomiting; at
14 days, this number was significantly reduced by half
(p = 0.002, McNemar test). 6 patients had bloody
stools at inclusion, decreasing to 3 after 14 days, and
to none after 45. Normal stool consistency (formed or
soft stools), present in 66.7 % (20/30) of infants at in-
clusion, significantly increased to 90.0 % (27/30) after
14 days (p = 0.020, McNemar test).
Digestive discomfort, present in 25 patients at in-
clusion, of which 12 patients had symptoms of mod-
erate/severe intensity, decreased to 17 patients after
14 days (p = 0.011, McNemar test), of which only one
patient had symptoms of moderate/severe intensity.
Stool frequency did not significantly change after 14
and 45 days. 73.3 % (22/30) of infants had 1–3
stools/day on day 14. Agitated sleep significantly de-
creased from 83.3 % (25/30) of infants at baseline to
43.3 % (13/30) after 14 days (p = 0.001, McNemar
test).
Table 2 Characteristics related to DBPCFC of the FAS
population (N = 30)
Characteristics
Immediate reactions to CMP, N (%) 22 (73.3)
Types of immediate reactions to CMP, N (%)
Digestive signs 19 (86.4)
Local cutaneous signs 7 (31.8)
General cutaneous signs 6 (27.3)
Laryngeal edema 2 (9.1)
Bronchospasm 1 (4.5)
Delayed reactions to CMP, N (%) 10 (33.3)
Types of delayed reactions to CMP, N (%)
Digestive 8 (80.0)
Cutaneous 5 (50.0)
Cumulative dose of non-hydrolyzed CMP-based
formula eliciting immediate reactions, median
[minimum-maximum], ml
15 [5–95]
Time for eliciting immediate reactions, mean
(± SD), minutes
83.8 (16.1)
N number of subjects
Table 3 Change from baseline of CoMiSS and parameters
contributing to the CoMiSS at 14 days
Inclusion (N = 30) D14 (N = 30)
CoMiSS, mean (± SD) 7.4 (4.4) 3.2 (2.3)*
Regurgitation scorea, mean (± SD) 1.6 (1.6) 0.9 (1.0)*
Crying scorea, mean (± SD) 1.7 (1.1) 0.8 (0.6)*
Stool consistency, N (%)
Type I/II (hard) 6 (20.0) 2 (6.7)
Type III/IV (formed) 16 (53.3) 20 (66.7)
Type V (soft) 4 (13.3) 7 (23.3)
Type VI (mushy) 3 (10.0) 1 (3.3)
Type VII (watery) 1 (3.3) 0 (0.0)
Urticaria, N (%)
Presence 7 (23.3) 0 (0.0)
Absence 23 (76.7) 30 (100.0)
Eczema, N (%)
Head, neck, trunk
Absence 21 (70.0) 24 (80.0)
Mild 3 (10.0) 4 (13.3)
Moderate 5 (16.7) 2 (6.7)
Severe 1 (3.3) 0 (0.0)
Arms, hands, legs, feet
Absence 23 (76.7) 24 (80.0)
Mild 3 (10.0) 3 (10.0)
Moderate 3 (10.0) 3 (10.0)
Severe 1 (3.3) 0 (0.0)
Respiratory symptoms, N (%)
Absence 25 (83.3) 28 (93.3)
Mild 4 (13.3) 1 (3.3)
Moderate 1 (3.3) 1 (3.3)
D day, N number of subjects
*P-values vs. inclusion < 0.001 (Wilcoxon’s test)
aSub-scores included in the calculation of the CoMiSS
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The mean (±SD) feeding duration was 113.6 (±27.8)
days and the mean daily intake of study formula was
higher than 600 ml/day during the entire study course.
33 AEs were reported in 24 patients: 48.5 % (16/33) were
respiratory infections and one third gastroenteritis. None
were related to the tested formula nor led to feeding dis-
continuation of the tested formula. No serious AEs were
reported. Between birth and inclusion, the mean (±SD)
WFA and LFA z-scores had significantly decreased by 0.7
(±1.0) and 0.6 (±1.1), respectively (p < 0.001; p = 0.003,
Student’s test). All growth indices, negative at study inclu-
sion, showed significant improvements within the 4-
month study (Table 4). As of 14 days of feeding, 73.3 %
(22/30) of the investigators and 71.4 % (20/28) of the par-
ents were globally satisfied with the formula, 75.8 % (22/
29) of parents being satisfied or very satisfied in particular
with their child’s acceptance of the formula’s taste.
Discussion
This study demonstrates the hypoallergenicity, efficacy
and positive effect on growth catch-up of the studied
eHCF in infants with CMA. As all infants with CMA,
confirmed by a DBPCFC, tolerated the tested formula,
this formula meets the hypoallergenicity criteria of the
American Academy of Pediatrics [10].
In this study, CMA was proven in all subjects by a
DBPCFC, the gold standard for CMA diagnosis [3, 4, 7].
In addition, in the absence of a reference group, which
allows controlling for the natural evolution of the
disease, the symptom evolution was first evaluated
2 weeks after study enrollment, which is close enough to
the time of diagnosis to exclude the possibility of a nat-
ural evolution of symptoms [3, 4].
The efficacy of the studied eHCF was thoroughly doc-
umented in this trial, by assessing all parameters con-
tributing to an existing Symptoms-Based Score (SBS)
[21–23]. A working group recently considered the SBS
as a valuable tool for evaluating and quantifying the evo-
lution of CMA symptoms during therapeutic interven-
tions and renamed it Cow’s Milk-related Symptom Score
(CoMiSS) [14]. Here, this score was significantly reduced
as early as 14 days after eHCF feeding initiation. A simi-
lar evolution was reported in previous studies following
young infants with proven CMA and under elimination
diet by using this score. In 37 and 34 infants fed respect-
ively an eHF based on rice proteins and an eHCF, the
mean SBS (±SD) significantly decreased after one
month-feeding from 13.0 (±5.2) to 3.5 (±2.3) and from
14.3 (±3.3) to 5.7 (±3.7) [22, 23]. In another study, 59 in-
fants fed an eHCF or an eHF based on whey proteins
(eHWF) showed a mean SBS of 13.6 (±1.7) at inclusion
that decreased to 5.1 (±3.4) after one month-feeding
[21]. Compared with these previous results, the mean
CoMiSS value at inclusion reported here was relatively
small and lower than the value (≥12) which could have
an 80 % positive predictive value for CMA diagnosis at
the start of an elimination diet followed by a decrease to
≤6 under an elimination diet with eHF. This can be
Table 4 Growth indices at inclusion and follow-up visits (D45, D90 and D120)
Inclusion D45 D90 D120
Age, mean (± SD), months 4.8 (3.0) 6.3 (3.1) 7.8 (3.0) 8.7 (3.0)
Weight-for-age z-score, mean (± SD) −0.8 (0.8) −0.2 (0.7) 0.1 (0.7) 0.4 (0.8)
N 29 29 29
P-values vs. baseline <0.001a <0.001a <0.001a
Length-for-age z-score, mean (± SD) −0.7 (1.0) −0.3 (1.2) 0.0 (1.2) 0.4 (1.1)
N 29 29 28
P-values vs. baseline 0.008a <0.001a <0.001a
Weight-for-length z-score, mean (± SD) −0.4 (1.1) 0.0 (0.8) 0.2 (0.6) 0.3 (0.7)
N 29 29 28
P-values vs. baseline 0.002a <0.001a <0.001a
Body mass index-for-age z-score, mean (± SD) −0.6 (1.0) −0.1 (0.8) 0.2 (0.7) 0.3 (0.8)
N 29 29 28
P-values vs. baseline 0.001a <0.001a <0.001a
Head circumference-for-age z-score, mean (± SD) −0.3 (1.2) 0.2 (1.0) 0.7 (0.8) 1.1 (0.9)
N 27 29 29
P-values vs. baseline <0.001b <0.001b <0.001b
D day, N number of subjects
aStudent’s test
bWilcoxon’s test
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explained by the fact that 80.0 % of enrolled infants were
on an elimination diet, more than half with eHF based
on CMP (54.2 %), one quarter with AAF and 20.8 % with
vegetable-based formulas.
In the absence of a validated CMA severity score [14],
previous similar studies frequently focused on the
SCORAD index evolution, a validated tool for assess-
ment of eczema severity [17], especially since some
eHFs, but not all [24], based on casein [25, 26] or whey
proteins [25, 27] efficiently induced a decrease in this
score in CMA patients. In this present study, less than
one third of patients had eczema at inclusion, and their
SCORAD index significantly decreased 14 and 45 days
after eHCF feeding initiation.
CMA treatment relies on dietary elimination of intact
CMP [3, 4, 8] which may induce nutritional deficiencies
in children in case of an inadequate elimination diet. As
shown by negative growth indices in children with CMA
at study enrollment [26], CMA is frequently associated
with a growth deficit [28, 29]. The mechanisms for im-
paired growth are not entirely clear but may rise from a
sustained inflammation and subsequent reduced bio-
availability or loss of nutrients in the gastrointestinal
tract, while metabolic requirements may be increased by
skin inflammation and disrupted sleep [12]. A delayed
diagnosis and thus a delay in initiation of an appropriate
dietary management is a risk factor for impaired growth
in children with a food allergy [30]. Here, CMA symp-
toms appeared during the first months of life, as previ-
ously reported [5, 6], and the median [range] delay
between their appearance and implementation of an
elimination diet was 1.3 [0.0–34.9] weeks. As shown be-
fore [26, 31, 32], WFA and LFA z-scores significantly de-
creased between birth and study inclusion. Feeding with
the study eHCF enabled growth normalization in line
with WHO standards, as already observed for eHCF
feeding [23, 26, 32].
In this study, whatever their CMA type, IgE-
mediated or not, all infants tolerated the eHCF during
4 months, and notably with consumptions of high
volumes. Parents sometimes ask for an eHF feeding
change for various reasons, for example because of a
poor taste acceptability—eHFs are known for their
bitterness [3, 4, 9, 33, 34]—or for poor digestive com-
fort including regurgitations [35]. All infants who
were already on an elimination diet for various time
periods and with different types of formulas devoid of
non-hydrolyzed CMP tolerated the studied eHCF.
Conclusions
The tested thickened eHCF was tolerated during
4 months by all infants with CMA proven by a DBPCFC,
either IgE or non-IgE mediated and whether already fed
or not an elimination diet. The formula feeding
efficiently reduced the SCORAD index in patients with
eczema and the CoMiSS, a recently developed tool to
follow allergy symptoms, in all subjects. This study was
adequately powered to demonstrate the hypoallergeni-
city of the studied formula, but the results observed on
allergy symptoms and growth indices deserve confirm-
ation in a larger sample.
The CONSORT guidelines [36], when applicable, were
followed for reporting data of this study.
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